All posts

Follow Us

LinkedInInstagramX
Annual ResultsArchiveLast updated 16 November 20263 min read

Vanta Bioscience (VANTABIO) Q4 FY26 Posts Q4 Profit on a Sharp Revenue Spike and Lower Costs

The preclinical CRO swung to a profit in the March quarter, but the surge was driven by a sharp drop in expenses and a low base, not recurring operational strength.

By Anant Kacholia, HexaWealth Research · Created 16 November 2026

Vanta Bioscience reported a net profit of ₹1.93 crore for Q4 FY26, a sharp swing from losses. Revenue surged over 400% sequentially, but the profit was underpinned by a dramatic, one-time fall in total expenses.

For Vanta Bioscience, a preclinical contract research organization, the March quarter brought a dramatic but deceptive turn. The company swung to a profit after a long stretch of losses, yet the underlying business remains fragile and heavily reliant on debt.

The quarter's numbers tell a story of extremes. Revenue jumped to ₹1.51 crore, a 357% increase from a very weak year-ago quarter. More strikingly, net profit landed at ₹1.93 crore, a sharp reversal from a ₹1.37 crore loss last year. This profit was not driven by a surge in core operations but by a collapse in total expenses, which turned negative at ₹0.21 crore.

Revenue & profit

Revenue (₹ Cr)

Net Profit (₹ Cr)

Revenue & profitQ4 FY24 3.55, Q2 FY25 1.03, Q4 FY25 0.33, Q2 FY26 0.30, Q4 FY26 1.51. Q4 FY24 -1.78, Q2 FY25 -2.07, Q4 FY25 -1.37, Q2 FY26 -1.82, Q4 FY26 1.93-4-2024Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 3.55
  • Revenue (₹ Cr), Q2 FY25: 1.03
  • Revenue (₹ Cr), Q4 FY25: 0.33
  • Revenue (₹ Cr), Q2 FY26: 0.30
  • Revenue (₹ Cr), Q4 FY26: 1.51
  • Net Profit (₹ Cr), Q4 FY24: -1.78
  • Net Profit (₹ Cr), Q2 FY25: -2.07
  • Net Profit (₹ Cr), Q4 FY25: -1.37
  • Net Profit (₹ Cr), Q2 FY26: -1.82
  • Net Profit (₹ Cr), Q4 FY26: 1.93

Revenue (₹ Cr)

Revenue (₹ Cr)Q4 FY24 3.55, Q2 FY25 1.03, Q4 FY25 0.33, Q2 FY26 0.30, Q4 FY26 1.5101234Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 3.55
  • Revenue (₹ Cr), Q2 FY25: 1.03
  • Revenue (₹ Cr), Q4 FY25: 0.33
  • Revenue (₹ Cr), Q2 FY26: 0.30
  • Revenue (₹ Cr), Q4 FY26: 1.51

Net Profit (₹ Cr)

Net Profit (₹ Cr)Q4 FY24 -1.78, Q2 FY25 -2.07, Q4 FY25 -1.37, Q2 FY26 -1.82, Q4 FY26 1.93-4-2024Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Net Profit (₹ Cr), Q4 FY24: -1.78
  • Net Profit (₹ Cr), Q2 FY25: -2.07
  • Net Profit (₹ Cr), Q4 FY25: -1.37
  • Net Profit (₹ Cr), Q2 FY26: -1.82
  • Net Profit (₹ Cr), Q4 FY26: 1.93
MetricCurrentQ4 FY26Same quarter LYQ4 FY25
Revenue (₹ Cr)
1.51YoY +358%
0.33
Net Profit (₹ Cr)
1.93YoY +241%
-1.37

The accounting shift behind the profit

The negative expense figure is the key to the quarter. According to data from Clartha.com, this reflects a significant reversal in provisions or write-backs, not a sustainable reduction in operating costs. For the full year, The Economic Times notes that a staggering 42.8% of operating revenue went towards interest expenses, highlighting the crushing weight of debt.

This debt burden is structural. The company's debt-to-equity ratio stands at 1.8, and its interest coverage is thin. While the quarterly interest expense turned to a small income of ₹0.11 crore, the annual figure of ₹0.78 crore remains a heavy load on its modest ₹1.82 crore annual revenue.

A subsidiary yet to contribute

Further clouding the path to stability is an inactive subsidiary. The company's annual report, cited by Scanx.trade, shows that Vanta Clinical Research Limited has not commenced commercial operations. Auditors also flagged non-provision for gratuity and delays in statutory filings, adding compliance overhang.

Live Chart

· VANTABIO

(BSE)

ISIN: INE695X01011

The market for preclinical CRO services in India is projected to grow, with MarkWide Research forecasting a 13.7% CAGR through 2036. Yet, Vanta's ability to capture this demand is constrained by its financial position and operational scale.

Key Points

  • The Q4 FY26 profit of ₹1.93 crore was primarily due to a one-time, sharp decline in total expenses, which turned negative.
  • The company carries a high debt-to-equity ratio of 1.8, with interest consuming a large portion of its annual operating revenue.
  • A key subsidiary remains non-operational, and auditors have highlighted delays in statutory compliances.
  • Full-year revenue for FY26 declined 7.3% to ₹1.82 crore, indicating the business has not yet found a stable growth trajectory.

Hexa Perspective

This quarter is a pause in a longer narrative of financial stress, not a reset. The profit is an accounting artifact, not evidence of operating leverage. The core challenge remains a debt-heavy balance sheet trying to support a very small revenue base in a capital-intensive business.

For the turnaround to be credible, Vanta needs to demonstrate it can win and execute contracts that generate consistent, growing revenue without relying on exceptional expense reversals. Until then, the high debt and thin interest coverage keep the financial structure precarious.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Vanta Bioscience (VANTABIO) Q4 FY26 results, revenue and profits.

Frequently asked questions

What were Vanta Bioscience's Q4 FY26 results?
Vanta Bioscience reported a net profit of ₹1.93 crore on revenue of ₹1.51 crore for the quarter ended March 2026. This represented a major swing from a loss of ₹1.37 crore in the same quarter last year, driven largely by a sharp, one-time drop in total expenses.
Why did Vanta Bioscience's Q4 FY26 profit jump despite low revenue?
Vanta Bioscience's Q4 profit of ₹1.93 crore was primarily due to a dramatic reduction in total expenses, which turned negative to ₹0.21 crore. Data from Clartha.com suggests this was likely due to accounting reversals of provisions, not sustainable cost savings from core operations.
What is Vanta Bioscience's debt-to-equity ratio?
Vanta Bioscience's debt-to-equity ratio was 1.8 as of the end of FY26. This high leverage indicates significant debt on its balance sheet relative to shareholder equity, a key financial risk for the company.
What was Vanta Bioscience's revenue in Q4 FY26?
Vanta Bioscience's revenue was ₹1.51 crore in the fourth quarter of FY26 (March 2026). This was a large increase from the ₹0.30 crore reported in the previous quarter, but still below levels seen in earlier years.
What was Vanta Bioscience's net profit in Q4 FY26?
Vanta Bioscience's net profit for Q4 FY26 (March 2026) was ₹1.93 crore. This was a significant improvement from a net loss of ₹1.37 crore in the year-ago quarter, though the gain was largely non-operational.
Why were Vanta Bioscience's total expenses negative in Q4 FY26?
Vanta Bioscience reported negative total expenses of ₹0.21 crore in Q4 FY26. This unusual figure, based on data from Clartha.com, typically indicates accounting reversals of previous provisions or write-backs, rather than a normal operating cost structure.
What is the status of Vanta Bioscience's subsidiary?
According to its annual report, Vanta Bioscience's wholly-owned subsidiary, Vanta Clinical Research Limited, had not commenced commercial operations as of March 31, 2026. This limits the company's operational scale and revenue potential.
Did Vanta Bioscience's auditors raise any concerns?
Yes. For FY26, the statutory auditors highlighted an emphasis of matter regarding non-provision for gratuity. A secretarial audit also noted delays in filing certain statutory forms and outstanding statutory dues, as reported by Scanx.trade.
What is the outlook for India's preclinical CRO market?
The India preclinical CRO market is projected to grow at a compound annual rate of 13.7% from 2026 to 2036, according to MarkWide Research. This growth is driven by pharmaceutical outsourcing and regulatory streamlining, though pricing pressure remains a challenge.
Vanta Bioscience H2 FY26 Results: Turns Profitable, Net Profit ₹1.9 Cr
For the half-year ended March 2026 (H2 FY26), Vanta Bioscience reported a net profit of ₹1.9 crore on revenue of ₹1.5 crore, as per an Alfafinder.com announcement. This result marked a return to profitability from a loss in the prior-year period.